A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics

Summary

Caribbean Hispanics are a population with a disproportionately high prevalence of cardio-metabolic disorders but with a limited expectation of benefits from current pharmacogenetic algorithms derived mainly in subjects of relatively pure ancestry. The investigators focus on warfarin responses to develop urgently-needed DNA-driven prescription guidelines for this population, who have arisen from European, West African and Amerindian genomic origins to produce a highly heterogeneous population. Our project combines admixture analysis and DNA-sequencing with development of more accurate rules for better predictability of warfarin dosing to immediately serve this medically underserved population.

Conditions

• Atrial Fibrillation
• Deep Vein Thrombosis
• Cardiac Valvular Insufficiency
• Coagulopathies
• Pulmonary Embolism

Interventions

GENETIC

Genotype-guided

Individual warfarin dose adjustments by using a pharmacogenetically driven algorithm

OTHER

Standard-of-Care

Individual warfarin dose adjustments by using a clinically driven algorithm (standard care)

Sponsors & Collaborators

• National Institute on Minority Health and Health Disparities (NIMHD)

  collaborator NIH

• Genomas, Inc

  collaborator INDUSTRY

• University of Puerto Rico

  lead OTHER

Principal Investigators

• Jorge Duconge, PhD · University of Puerto Rico Medical Sciences Campus

• Graciela M. Vega-Debien, BSc · University of Puerto Rico Medical Sciences Campus

• Angel Lopez-Candales, MD · University of Puerto Rico Medical Sciences Campus

• Alga S. Ramos, PharmD · Miami VA Hospital

Eligibility

Min Age

21 Years

Max Age

90 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2016-01-31

Primary Completion

2022-05-17

Completion

2022-05-17

Countries

• United States
• Puerto Rico

Study Locations